After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and development, particularly in clinical trials.
I’ve worked in clinical trials for twenty years. For most of that time, the core processes and challenges have been fairly consistent, with incremental improvements along the way.
Biopharma companies are increasingly turning to artificial intelligence (AI) to enhance customer-focused commercial strategies, driving more tailored engagement and improved operational eff
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.